Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy

Retina-Vitreus

Volumn 18, Issue 1, 2010, Pages 52-55

  Fulda, Emiliano ^a   Ariza, Enrique ^a   Lopez, Antonio ^a   Graue, Federico ^a  

^a INSTITUTE OF OPHTHALMOLOGY CONDE DE VALENCIANA   (Mexico)

Author keywords

Avastin; Diabetic retinopathy; PRP

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HEMIRETINAL PHOTOCOAGULATION; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PANRETINAL PHOTOCOAGULATION; RETINA FLUORESCEIN ANGIOGRAPHY; RETREATMENT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77953451252     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ferrara N.: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
2. Ferrara N, Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25. (Pubitemid 27076453)
3. Adamis AP, Shima DT.: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118. (Pubitemid 40365933)
4. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
5. Adamis, et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71. (Pubitemid 26026196)
6. S.C. Kaufman, et al.: Factors Associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Invs Ophtha and Visu Scien. 1989;30. No 1.
7. L.I. Rand, et al.: Factors influencing the development of visual loss in advanced diabetic retinopaty. Diabetic Retinopathy Study Report #10. Invs Ophtha and Visu Scien. 1988;28. No 2.
8. P.J. Rosenfeld, et al.: Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthal. 2005;6:1035-1047.
9. R. Avery, et al.: Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration, Ophthalm. 2006;3:363-372.
10. Y. Chen, et al.: Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration: A Short-term Study, Amer Jour of Ophthal. 2007;143:510-512. (Pubitemid 46298546)
11. Wai-Man Chan, et al.: Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin, Amer Jour of Ophthal. 2007;143:977-983.
12. J. F. Arevalo, et al.: Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group. Jour of Catar & Refrac Surg. 2007;33:2098-2105. (Pubitemid 350167520)
13. Haritoglou C, et al.: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005. (Pubitemid 44973218)
14. Ates Yanyali, et al.: Bevacizumab (avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes. Amer Jour of Ophth. 2007;144:124-126.
15. Martin S. Spitzer, et al.: Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. Jour of Catar & Refra Surg. 2008;34:70-75. (Pubitemid 350299767)
16. Milko E. et al Intravitreal Bevacizumab (avastin ®) in the Treatment of Neovascular Glaucoma. Amer Jour of Ophth. 2006;142:1054-1056. (Pubitemid 44853889)
17. Silva Paula, et al Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophth Scand. 2006;84:556-557. (Pubitemid 44102857)
18. Ciro Costagliola, et al.: Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation. Amer Jour of Ophth. 2007;144,449-451. (Pubitemid 47336935)
19. Costa RA, et al.: Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149. (Pubitemid 46245639)
20. Ebru Eren, et al.: Regression of neovascular posterior capsule vessels by intravitreal bevacizumab. Jour of Catar & Refra Surg. 2007;33:1113-1115.
21. Avery RL.: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-354.
22. Yusuke Oshima, et al.: Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic Retinopathy, Amer Jour of Ophth. 2006;142:155-157.
23. J.R. Costa et al.: Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26:1006-1013.
24. Spaide RF, et al.: Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
25. Chen E, et al.: Use of intravitreal bevacizumab as a preoperative adjunct for fractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-700.
26. Bakri SJ.: Pharmacokinetics of Intravitreal bevacizumab. Ophthalmology. 2007;114:855-859.
27. ARVO 2007 poster 1419/B475 P. Tsai. Intravitreal Bevacizumab (Avastin) in Patients With Proliferative Diabetic Retinopathy.
28. ARVO 2007 poster 1414/B470 Oliveira Neto. Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy.
29. ARVO 2007 poster 1429/B485 A. Saucedo-Castillo. Intravitreal Bevacizumab (Avastin) in Proliferative Diabetic Retinopathy.
30. R. Avery, et al.: Intravitreal Bevazicumab (Avastin) in the Treatment of Proliferative Retinopathy. Ophthalm. 2006;113.
31. Friedlander.: Vanishing disc neovascularization following intravitreal bevacizumab injection. Arch Ophth. 2006.